Free Trial
NASDAQ:BLFS

BioLife Solutions Q1 2025 Earnings Report

BioLife Solutions logo
$25.27 +0.67 (+2.72%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$25.28 +0.01 (+0.04%)
As of 05/2/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioLife Solutions EPS Results

Actual EPS
N/A
Consensus EPS
-$0.03
Beat/Miss
N/A
One Year Ago EPS
N/A

BioLife Solutions Revenue Results

Actual Revenue
N/A
Expected Revenue
$22.22 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioLife Solutions Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

BioLife Solutions Earnings Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
See More BioLife Solutions Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioLife Solutions? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioLife Solutions and other key companies, straight to your email.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

View BioLife Solutions Profile

More Earnings Resources from MarketBeat